BSE:506820

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. More Details

Risk Analysis

No risks detected for 506820 from our risk checks.


Snowflake Analysis

Flawless balance sheet with questionable track record.


Similar Companies

Share Price & News

How has AstraZeneca Pharma India's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 506820 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.4%

506820

-3.2%

IN Pharmaceuticals

-0.6%

IN Market


1 Year Return

77.9%

506820

52.6%

IN Pharmaceuticals

2.2%

IN Market

Return vs Industry: 506820 exceeded the Indian Pharmaceuticals industry which returned 52.6% over the past year.

Return vs Market: 506820 exceeded the Indian Market which returned 2.2% over the past year.


Shareholder returns

506820IndustryMarket
7 Day-0.4%-3.2%-0.6%
30 Day-0.2%-4.3%0.2%
90 Day23.8%13.4%6.7%
1 Year78.0%77.9%54.5%52.6%3.9%2.2%
3 Year339.4%338.9%26.9%23.4%2.6%-2.4%
5 Year258.3%257.8%-0.6%-4.1%41.3%30.8%

Price Volatility Vs. Market

How volatile is AstraZeneca Pharma India's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AstraZeneca Pharma India undervalued compared to its fair value and its price relative to the market?

154.76x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 506820 (₹4290.8) is trading above our estimate of fair value (₹434.16)

Significantly Below Fair Value: 506820 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 506820 is poor value based on its PE Ratio (154.8x) compared to the IN Pharmaceuticals industry average (23x).

PE vs Market: 506820 is poor value based on its PE Ratio (154.8x) compared to the Indian market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 506820's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 506820 is overvalued based on its PB Ratio (29.4x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is AstraZeneca Pharma India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AstraZeneca Pharma India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AstraZeneca Pharma India performed over the past 5 years?

35.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 506820 has high quality earnings.

Growing Profit Margin: 506820's current net profit margins (8.4%) are lower than last year (9%).


Past Earnings Growth Analysis

Earnings Trend: 506820 has become profitable over the past 5 years, growing earnings by 35.4% per year.

Accelerating Growth: 506820's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 506820 had negative earnings growth (-0.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 506820's Return on Equity (19%) is considered low.


Next Steps

Financial Health

How is AstraZeneca Pharma India's financial position?


Financial Position Analysis

Short Term Liabilities: 506820's short term assets (₹5.4B) exceed its short term liabilities (₹3.3B).

Long Term Liabilities: 506820's short term assets (₹5.4B) exceed its long term liabilities (₹146.8M).


Debt to Equity History and Analysis

Debt Level: 506820 is debt free.

Reducing Debt: 506820 had no debt 5 years ago.

Debt Coverage: 506820 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 506820 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is AstraZeneca Pharma India current dividend yield, its reliability and sustainability?

0.046%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 506820's dividend (0.046%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.57%).

High Dividend: 506820's dividend (0.046%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).


Stability and Growth of Payments

Stable Dividend: 506820 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 506820 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 506820 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 506820's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average management tenure


CEO

Gagan Bedi (49 yo)

3.25yrs

Tenure

₹48,230,765

Compensation

Mr. Gagandeep Singh Bedi also known as Gagan, has been Managing Director of AstraZeneca Pharma India Ltd. since July 1, 2017 and serves as its Country President. He held various roles as a Business Directo ...


CEO Compensation Analysis

Compensation vs Market: Gagan's total compensation ($USD657.53K) is about average for companies of similar size in the Indian market ($USD597.56K).

Compensation vs Earnings: Gagan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Gagandeep Bedi
MD, Country President & Executive Director3.25yrs₹48.23mno data
Rajesh Marwaha
CFO & Executive Director3.83yrs₹24.51mno data
Pratap Bhuvanagiri
Company Secretary3.67yrs₹3.73mno data
Smita Saha
Vice President of Human Resourcesno data₹12.28mno data
Richard Cheeseman
Head of Engineering & Facilitiesno datano datano data
José Baselga
Executive VP1.75yrsno datano data
Vimlesh Maheshwari
Finance Controllerno datano datano data
K. Shenoy
Director of Regulatory26.42yrs₹3.05mno data
Ramesh Venkatapathi
Director of Quality Assurance & Technical Services38.92yrs₹2.45mno data
Paurus Irani
Global Medical Affairs Leader - Infection12.17yrs₹9.63mno data
Rajeev Nagi
Vice President of Institutions & International Businessno data₹6.77mno data

6.2yrs

Average Tenure

53yo

Average Age

Experienced Management: 506820's management team is seasoned and experienced (6.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gagandeep Bedi
MD, Country President & Executive Director3.25yrs₹48.23mno data
Rajesh Marwaha
CFO & Executive Director3.83yrs₹24.51mno data
Revathy Ashok
Independent Non-Executive Director3.83yrs₹1.20mno data
Narayan Seshadri
Independent Chairman of the Board3.83yrs₹1.50mno data
Kimsuka Narsimhan
Independent Non-Executive Directorno data₹1.10mno data
Weiying Sarah Wang
Non-Executive Director1.58yrsno datano data
Ankush Nandra
Additional Non-Executive Director0.42yrno datano data

3.5yrs

Average Tenure

56yo

Average Age

Experienced Board: 506820's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AstraZeneca Pharma India Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AstraZeneca Pharma India Limited
  • Ticker: 506820
  • Exchange: BSE
  • Founded: 1979
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹107.270b
  • Shares outstanding: 25.00m
  • Website: https://www.astrazeneca.com/india

Number of Employees


Location

  • AstraZeneca Pharma India Limited
  • Manyata Embassy Business Park
  • Block N1, 12th Floor
  • Bengaluru
  • Karnataka
  • 560045
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
506820BSE (Mumbai Stock Exchange)YesEquity SharesININRJul 2000
ASTRAZENNSEI (National Stock Exchange of India)YesEquity SharesININRJul 2000

Biography

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Bri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 12:34
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.